Biolidics

Executive Summary

Biolidics Limited is a Singapore-based diagnostics company that develops and commercializes label-free microfluidic platforms for circulating tumor cell (CTC) enrichment and rapid immunoassay tests for infectious diseases. Its flagship ClearCell® FX1 System isolates viable CTCs for downstream liquid biopsy analysis in oncology, while the ClearEpi line provides SARS-CoV-2 antigen and neutralizing antibody rapid test kits. As a commercial-stage public company, Biolidics aims to lower healthcare costs and improve clinical outcomes through innovative, automated solutions. With a focus on non-invasive cancer diagnostics and point-of-care infectious disease testing, the company is likely to expand beyond COVID-19 into other infectious diseases and broaden oncology applications. It continues to pursue regulatory approvals and strategic partnerships to enhance its global commercial presence. Given the competitive landscape and evolving market dynamics, Biolidics' near-term growth will depend on successful product differentiation and market adoption of its CTC platform.

Upcoming Catalysts (preview)

• H2 2026Regulatory clearance (FDA 510(k) or CE mark) for a new liquid biopsy assay on ClearCell FX1 for a specific cancer type40% success
• H1 2027Launch of a rapid test for a new infectious disease (e.g., dengue, influenza) under the ClearEpi brand35% success
• H2 2026Strategic distribution partnership for ClearCell FX1 in a major market (e.g., Europe or United States)30% success